Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and Marker Therapeutics (NASDAQ:MRKR – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.
Profitability
This table compares Monte Rosa Therapeutics and Marker Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Monte Rosa Therapeutics | -186.24% | -30.14% | -20.35% |
| Marker Therapeutics | N/A | -56.96% | -47.82% |
Insider & Institutional Ownership
80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Monte Rosa Therapeutics and Marker Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Monte Rosa Therapeutics | 1 | 2 | 8 | 1 | 2.75 |
| Marker Therapeutics | 1 | 0 | 2 | 1 | 2.75 |
Monte Rosa Therapeutics currently has a consensus target price of $26.44, indicating a potential upside of 191.95%. Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 986.96%. Given Marker Therapeutics’ higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Monte Rosa Therapeutics.
Earnings & Valuation
This table compares Monte Rosa Therapeutics and Marker Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Monte Rosa Therapeutics | $123.67 million | 6.26 | -$38.63 million | ($1.40) | -6.47 |
| Marker Therapeutics | $3.55 million | 4.32 | -$12.16 million | ($0.41) | -2.24 |
Marker Therapeutics has lower revenue, but higher earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Monte Rosa Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.
Summary
Monte Rosa Therapeutics beats Marker Therapeutics on 7 of the 13 factors compared between the two stocks.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.
About Marker Therapeutics
Marker Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s platform is designed to produce multi-antigen-targeted T cells, which recognize several tumor-associated antigens rather than a single target. Marker Therapeutics has been developing these therapies for use in patients with hematologic malignancies and solid tumors. The company’s investigational pipeline has included MT-601, an autologous multiTAA-specific T-cell therapy being evaluated for certain solid tumors, and MT-401, a related therapy developed for acute myeloid leukemia.
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
